Ady Permana

Diagnos Laboratorium merupakan bagian dari BMHS (Bundamedik Healthcare System). Hadir sebagai kebutuhan masyarakat, yang berdiri dengan visi dan misi yang jelas. Kami menyediakan kualitas tinggi, handal, dan layanan laboratorium yang konsisten untuk semua mitra dan pelanggan Diagnos. Komitmen Kami “Diagnos Laboratorium lahir dari ekspektasi laboratorium yang memenuhi syarat, lengkap dan berorientasi pasien

Quadrant Biosciences is an epigenetic diagnostics company with a focus on the early detection of neurological disorders and other large-scale health issues. Revolutionary advancements in the early detection of autism spectrum disorder, Parkinson’s disease, and mTBI, through the application of the Clarifi® epigenetic diagnostic platform, could have a significant impact on the way clinicians approach the diagnosis and treatment of these serious conditions. In March 2020, we made the decision to pivot and allocate some of our resources to directly address the pandemic. By leveraging our expertise in RNA analysis, we have been able to be part of three exciting COVID-19 projects to aid in the detection of COVID-19 in individuals and communities across the U.S. In September 2020, The Clarifi COVID-19 Test Kit obtained Emergency Use Authorization (EUA) by the Food and Drug Administration (FDA) to be used for the diagnosis fo SARS-CoV-2.

Diagnos Laboratorium merupakan bagian dari BMHS (Bundamedik Healthcare System). Hadir sebagai kebutuhan masyarakat, yang berdiri dengan visi dan misi yang jelas. Kami menyediakan kualitas tinggi, handal, dan layanan laboratorium yang konsisten untuk semua mitra dan pelanggan Diagnos. Komitmen Kami “Diagnos Laboratorium lahir dari ekspektasi laboratorium yang memenuhi syarat, lengkap dan berorientasi pasien

Quadrant Biosciences is an epigenetic diagnostics company with a focus on the early detection of neurological disorders and other large-scale health issues. Revolutionary advancements in the early detection of autism spectrum disorder, Parkinson’s disease, and mTBI, through the application of the Clarifi® epigenetic diagnostic platform, could have a significant impact on the way clinicians approach the diagnosis and treatment of these serious conditions. In March 2020, we made the decision to pivot and allocate some of our resources to directly address the pandemic. By leveraging our expertise in RNA analysis, we have been able to be part of three exciting COVID-19 projects to aid in the detection of COVID-19 in individuals and communities across the U.S. In September 2020, The Clarifi COVID-19 Test Kit obtained Emergency Use Authorization (EUA) by the Food and Drug Administration (FDA) to be used for the diagnosis fo SARS-CoV-2.